Tolterodine for the treatment of overactive bladder

Stefano Salvatore, Maurizio Serati, Pierfrancesco Bolis

Research output: Contribution to journalArticlepeer-review


Background: The overactive bladder syndrome is a common condition affecting ∼12% of men and women. It is extremely disturbing with a great impact on quality of life. Its treatment involves a combination of behavioural and pharmacological therapy. The latter includes antimuscarinic drugs such as tolterodine. Objective: To review the safety and efficacy of tolterodine in the treatment of overactive bladder in comparison with other available antimuscarinic agents. Methods: A Pubmed search was carried out differentiating randomised, clinical trials; longitudinal, retrospective studies, and metanalysis on the use of tolterodine for overactive bladder treatment. In the comparison with other antimuscarinic agents, only randomised, clinical trials were considered. Results/conclusion: Tolterodine is available as immediate- or extended-release formulations. It has been extensively evaluated with long-term, randomised trials for safety and efficacy showing a significant improvement in overactive bladder symptoms with an excellent tolerability profile.

Original languageEnglish
Pages (from-to)1249-1255
Number of pages7
JournalExpert Opinion on Pharmacotherapy
Issue number7
Publication statusPublished - May 2008


  • Antimuscarinic agents
  • Decrusor overacrivity
  • Overactive bladder
  • Tolterodine

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Pharmacology, Toxicology and Pharmaceutics(all)


Dive into the research topics of 'Tolterodine for the treatment of overactive bladder'. Together they form a unique fingerprint.

Cite this